SAN DIEGO, Ca., May 9, 2011 — OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company’s tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical technology industry that is relied on by thousands of industry insiders every business morning.
The article noted that OncoSec is leveraging the successful treatment of cancers in early and late stage clinical trials of more than 400 patients to advance its proprietary drug technology delivery system, which enables highly targeted delivery of chemotherapy agents and DNA-based immunotherapies into solid tumors.
The article quoted OncoSec’s CEO, Punit Dhillon, who said: “…[OncoSec] is not your typical startup because we’re leveraging a lot of historical and clinical data, along with clinical experience.”
Dhillon foresees a large market opportunity for the OncoSec drug/device treatment system: “Our conservative estimate is at least four million people in the U.S. Where the larger market lies is in emerging markets. That could exponentially increase [the market],” he said.
The full article can be found at: http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=75423
About OncoSec Medical Inc.
Oncosec Medical’s (OTCBB: ONCS) novel ElectroOncology therapies combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents achieves selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. More information is available at www.oncosec.com.